Janux Therapeutics JANX Stock
Janux Therapeutics Price Chart
Janux Therapeutics JANX Financial and Trading Overview
| Janux Therapeutics stock price | 49.77 USD |
| Previous Close | 13.22 USD |
| Open | 13.22 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 12.88 - 13.22 USD |
| 52 Week Range | 10 - 23.64 USD |
| Volume | 51.97K USD |
| Avg. Volume | 124.52K USD |
| Market Cap | 548.02M USD |
| Beta (5Y Monthly) | 1.542983 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.32 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.5 USD |
JANX Valuation Measures
| Enterprise Value | 261.3M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.282258 |
| PEG Ratio (5 yr expected) | -0.74 |
| Price/Sales (ttm) | 60.414097 |
| Price/Book (mrq) | 1.7593338 |
| Enterprise Value/Revenue | 28.806 |
| Enterprise Value/EBITDA | -3.598 |
Trading Information
Janux Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.542983 |
| 52-Week Change | 19.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 23.64 USD |
| 52 Week Low | 10 USD |
| 50-Day Moving Average | 13.69 USD |
| 200-Day Moving Average | 14.78 USD |
JANX Share Statistics
| Avg. Volume (3 month) | 124.52K USD |
| Avg. Daily Volume (10-Days) | 110.81K USD |
| Shares Outstanding | 41.83M |
| Float | 6.6M |
| Short Ratio | 14.05 |
| % Held by Insiders | 1.44% |
| % Held by Institutions | 80.38% |
| Shares Short | 2.88M |
| Short % of Float | 20.01% |
| Short % of Shares Outstanding | 6.87% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -813.91% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -12.79% |
| Return on Equity (ttm) | -20.11% |
Income Statement
| Revenue (ttm) | 9.07M USD |
| Revenue Per Share (ttm) | 0.22 USD |
| Quarterly Revenue Growth (yoy) | 28.89% |
| Gross Profit (ttm) | -44829000 USD |
| EBITDA | -72617000 USD |
| Net Income Avi to Common (ttm) | -67108000 USD |
| Diluted EPS (ttm) | -1.65 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 316.88M USD |
| Total Cash Per Share (mrq) | 7.58 USD |
| Total Debt (mrq) | 25.54M USD |
| Total Debt/Equity (mrq) | 8.21 USD |
| Current Ratio (mrq) | 19.945 |
| Book Value Per Share (mrq) | 7.446 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -45311000 USD |
| Levered Free Cash Flow (ttm) | -30645750 USD |
Profile of Janux Therapeutics
| Country | United States |
| State | CA |
| City | La Jolla |
| Address | 11099 North Torrey Pines Road |
| ZIP | 92037 |
| Phone | 858 750 4700 |
| Website | https://www.januxrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 62 |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Q&A For Janux Therapeutics Stock
What is a current JANX stock price?
Janux Therapeutics JANX stock price today per share is 49.77 USD.
How to purchase Janux Therapeutics stock?
You can buy JANX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Janux Therapeutics?
The stock symbol or ticker of Janux Therapeutics is JANX.
Which industry does the Janux Therapeutics company belong to?
The Janux Therapeutics industry is Biotechnology.
How many shares does Janux Therapeutics have in circulation?
The max supply of Janux Therapeutics shares is 54.65M.
What is Janux Therapeutics Price to Earnings Ratio (PE Ratio)?
Janux Therapeutics PE Ratio is now.
What was Janux Therapeutics earnings per share over the trailing 12 months (TTM)?
Janux Therapeutics EPS is -1.32 USD over the trailing 12 months.
Which sector does the Janux Therapeutics company belong to?
The Janux Therapeutics sector is Healthcare.
Janux Therapeutics JANX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}